Skip to main content
SpringerLink
Log in

Development of Novel Diagnostic Pancreatic Tumor Biomarkers

  • Reference work entry
  • First Online:
Pancreatic Cancer

Abstract

As the incidence of pancreatic ductal adenocarcinoma cancer (PDAC) increases, the need to improve the outcome for patients with this deadly disease becomes all the more pressing. Earlier detection of PDAC has the potential to improve survival, and biomarkers that enable earlier diagnosis are sought after. Some of the challenges associated with developing new diagnostic biomarkers for PDAC are reviewed here, including the need for appropriate control groups and the necessity to account for established confounding factors such as obstructive jaundice. High-risk groups, including individuals with new-onset diabetes, are discussed, and the findings of studies utilizing samples from pre-diagnostic cohorts to monitor changes in biomarker levels occurring in the weeks and months prior to diagnosis of PDAC are appraised. Progress toward identification of specific biomarker types is provided, and a variety of sources of biomarkers are examined, including blood, urine, pancreatic juice, gut lavage fluid, and extracellular vesicles. Additionally, a range of biomarker types are reviewed, including protein biomarkers, circulating tumor cells, circulating tumor DNA, and microRNAs. New developments with respect to emerging biomarkers, such as metabolites, are also examined. While progress to date has been slow, clear advances are being made, and the promise of biomarkers with clinical utility is in reach.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 849.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,099.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001;41:347–66.

    Article  CAS  PubMed  Google Scholar 

  3. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24(33):5313–27.

    Article  CAS  PubMed  Google Scholar 

  4. Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37(3):269–74.

    Article  PubMed  Google Scholar 

  5. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010;467(7319):1109–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467(7319):1114–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1–7.

    Article  CAS  PubMed  Google Scholar 

  8. Yan L, Tonack S, Smith R, Dodd S, Jenkins RE, Kitteringham N, et al. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res. 2009;8(1):142–8.

    Article  CAS  PubMed  Google Scholar 

  9. Tonack S, Jenkinson C, Cox T, Elliott V, Jenkins RE, Kitteringham NR, et al. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. Br J Cancer. 2013;108(9):1846–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Nie S, Lo A, Wu J, Zhu J, Tan Z, Simeone DM, et al. Glycoprotein biomarker panel for pancreatic cancer discovered by quantitative proteomics analysis. J Proteome Res. 2014;13(4):1873–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European prospective investigation into cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr. 2002;5(6B):1113–24.

    Article  CAS  PubMed  Google Scholar 

  12. Menon U, Gentry-Maharaj A, Ryan A, Sharma A, Burnell M, Hallett R, et al. Recruitment to multicentre trials – lessons from UKCTOCS: descriptive study. BMJ. 2008;337:a2079.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol. 2009;10(4):327–40.

    Article  PubMed  Google Scholar 

  14. Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteome. 2014;9:305–315.

    Google Scholar 

  15. Jenkinson C, Elliott VL, Evans A, Oldfield L, Jenkins RE, O'Brien DP, et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus. Clin Cancer Res. 2016;22(7):1734–43.

    Article  CAS  PubMed  Google Scholar 

  16. Capello M, Cappello P, Linty FC, Chiarle R, Sperduti I, Novarino A, et al. Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models. J Hematol Oncol. 2013;6:67.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  17. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Huang Z, Liu F. Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis. Tumour Biol. 2014;35:5501–5514.

    Article  CAS  PubMed  Google Scholar 

  19. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16(1):37–52.

    Article  PubMed  Google Scholar 

  20. Nolen BM, Brand RE, Prosser D, Velikokhatnaya L, Allen PJ, Zeh HJ, et al. Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study. PLoS One. 2014;9(4):e94928.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  21. Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, et al. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer. 2013;119(3):522–8.

    Article  CAS  PubMed  Google Scholar 

  22. Brand RE, Nolen BM, Zeh HJ, Allen PJ, Eloubeidi MA, Goldberg M, et al. Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res. 2011;17(4):805–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res. 2012;11(3):1937–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Tiernan JP, Perry SL, Verghese ET, West NP, Yeluri S, Jayne DG, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer. 2013;108(3):662–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Poruk KE, Gay DZ, Brown K, Mulvihill JD, Boucher KM, Scaife CL, et al. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med. 2013;13(3):340–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Keane MG, Horsfall L, Rait G, Pereira SP. A case-control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open. 2014;4(11):e005720.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Petersen GM. Familial Pancreatic Adenocarcinoma. Hematol Oncol Clin North Am. 2015;29(4):641–53.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Sah RP, Nagpal SJ, Mukhopadhyay D, Chari ST. New insights into pancreatic cancer-induced paraneoplastic diabetes. Nat Rev Gastroenterol Hepatol. 2013;10(7):423–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Permert J, Ihse I, Jorfeldt L, von Schenck H, Arnqvist HJ, Larsson J. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159(2):101–7.

    CAS  PubMed  Google Scholar 

  30. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology. 2008;134(4):981–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Aggarwal G, Ramachandran V, Javeed N, Arumugam T, Dutta S, Klee GG, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta cells and mice. Gastroenterology. 2012;143(6):1510–7. e1

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hart PA, Baichoo E, Bi Y, Hinton A, Kudva YC, Chari ST. Pancreatic polypeptide response to a mixed meal is blunted in pancreatic head cancer associated with diabetes mellitus. Pancreatology. 2015;15(2):162–6.

    Article  CAS  PubMed  Google Scholar 

  33. Huang H, Dong X, Kang MX, Xu B, Chen Y, Zhang B, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles. Am J Gastroenterol. 2010;105(7):1661–9.

    Article  CAS  PubMed  Google Scholar 

  34. Hruban RH, Takaori K, Klimstra DS, Adsay NV, Albores-Saavedra J, Biankin AV, et al. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol. 2004;28(8):977–87.

    Article  PubMed  Google Scholar 

  35. Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12(3):183–97.

    Article  PubMed  Google Scholar 

  36. David A, Klibansky KMRL, Gordon SR, Gardner TB. The clinical relevance of the increasing incidence of intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2012;10(5):555–8.

    Article  Google Scholar 

  37. Chari ST, Kelly K, Hollingsworth MA, Thayer SP, Ahlquist DA, et al. Early detection of sporadic pancreatic cancer: summative review. Pancreas. 2015;44(5):693–712.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Rhim AD. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8(4):340–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van der Velde AG, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol. 2013;24(3):734–41.

    Article  CAS  PubMed  Google Scholar 

  42. Permuth-Wey J, Chen YA, Fisher K, McCarthy S, Qu X, Lloyd MC, et al. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas. PLoS One. 2015;10(1):e0116869.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  43. Li A, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19(13):3600–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Tonack S, Aspinall-O'Dea M, Neoptolemos JP, Costello E. Pancreatic cancer: proteomic approaches to a challenging disease. Pancreatology. 2009;9(5):567–76.

    Article  PubMed  Google Scholar 

  45. Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteome. 2014;113C:400–2.

    Google Scholar 

  46. Mirus JE, Zhang Y, Li CI, Lokshin AE, Prentice RL, Hingorani SR, et al. Cross-species antibody microarray interrogation identifies a 3-protein panel of plasma biomarkers for early diagnosis of pancreas cancer. Clin Cancer Res. 2015;21(7):1764–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, et al. Identification of a three-biomarker panel in urine for early detection of pancreatic adenocarcinoma. Clin Cancer Res. 2015;21(15):3512–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Park JY, Kim SA, Chung JW, Bang S, Park SW, Paik YK, et al. Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer. J Cancer Res Clin Oncol. 2011; https://doi.org/10.1007/s00432-011-0992-2.

  49. Okai T, Sawabu N, Takemori Y, Ohta H, Motoo Y, Kidani H. Levels of carcinoembryonic antigen and carbohydrate antigen (CA19-9) in pure pancreatic juice and sera in a patient with occult pancreatic cancer. J Clin Gastroenterol. 1992;15(2):162–4.

    Article  CAS  PubMed  Google Scholar 

  50. Rocker JM, Tan MC, Thompson LW, Contreras CM, DiPalma JA, Pannell LK. Comparative proteomic analysis of whole-gut lavage fluid and pancreatic juice reveals a less invasive method of sampling pancreatic secretions. Clin Transl Gastroenterol. 2016;7:e174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Tjensvoll K, Nordgard O, Smaaland R. Circulating tumor cells in pancreatic cancer patients: methods of detection and clinical implications. Int J Cancer. 2014;134(1):1–8.

    Article  PubMed  CAS  Google Scholar 

  52. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004;10(20):6897–904.

    Article  PubMed  Google Scholar 

  53. Khoja L, Backen A, Sloane R, Menasce L, Ryder D, Krebs M, et al. A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. Br J Cancer. 2012;106(3):508–16.

    Article  CAS  PubMed  Google Scholar 

  54. Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, et al. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer. Br J Cancer. 2016;114(12):1367–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Sun K, Jiang P, Chan KC, Wong J, Cheng YK, Liang RH, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112(40):E5503–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Bettegowda C, Sausen M, Leary R, Kinde I, Agrawal N, Bartlett B, et al. Detection of circulating tumor DNA in early and late stage human malignancies. Cancer Res. 2014;6(19). https://doi.org/10.1126/scitranslmed.3007094.

  57. Jenkinson C, Earl J, Ghaneh P, Halloran C, Carrato A, Greenhalf W, et al. Biomarkers for early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2015;9(3):305–15.

    Article  CAS  PubMed  Google Scholar 

  58. Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodriguez-Garrote M, et al. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15. https://doi.org/10.1186/s12885-015-1779-7.

  59. Taly V, Pekin D, Benhaim L, Kotsopoulos SK, Le Corre D, Li X, et al. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. Clin Chem. 2013;59(12):1722–31.

    Article  CAS  PubMed  Google Scholar 

  60. Kinugasa H, Nouso K, Miyahara K, Morimoto Y, Dohi C, Tsutsumi K, et al. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Cancer. 2015;121(13):2271–80.

    Article  CAS  PubMed  Google Scholar 

  61. Hadano N, Murakami Y, Uemura K, Hashimoto Y, Kondo N, Nakagawa N, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115(1):59–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Lin SB, Gregory RI. MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 2015;15(6):321–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Neault M, Mallette FA, Richard S. miR-137 modulates a tumor suppressor network-inducing senescence in pancreatic cancer cells. Cell Rep. 2016;14(8):1966–78.

    Article  CAS  PubMed  Google Scholar 

  64. Sun Y, Zhang TT, Wang CP, Jin XL, Jia CW, Yu SN, et al. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One. 2015;10(4):e0119783.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh S, Andrews J, et al. MicroRNA-345 induces apoptosis in pancreatic cancer cells through potentiation of caspase-dependent and -independent pathways. Br J Cancer. 2015;113(4):660–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Li J, Wu H, Li W, Yin L, Guo S, Xu X, et al. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-kappaB signaling. Oncogene. 2016.

    Google Scholar 

  67. Cote GA, Gore AJ, McElyea SD, Heathers LE, Xu H, Sherman S, et al. A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol. 2014;109(12):1942–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Morimura R, Komatsu S, Ichikawa D, Takeshita H, Tsujiura M, Nagata H, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer. 2011;105(11):1733–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Li AG, Yu J, Kim H, Wolfgang CL, Canto MI, Hruban RH, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013;19(13):3600–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, et al. MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404.

    Article  CAS  PubMed  Google Scholar 

  72. Akamatsu M, Makino N, Ikeda Y, Matsuda A, Ito M, Kakizaki Y, et al. Specific MAPK-associated microRNAs in serum differentiate pancreatic cancer from autoimmune pancreatitis. PLoS One. 2016;11(7):e0158669.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  73. Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, et al. Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. BBA-Mol Cell Res. 2015;1853(10):2392–403.

    CAS  Google Scholar 

  74. Botla SK, Savant S, Jandaghi P, Bauer AS, Mucke O, Moskalev EA, et al. Early epigenetic downregulation of microRNA-192 expression promotes pancreatic cancer progression. Cancer Res. 2016;76:4149–4159.

    Article  CAS  PubMed  Google Scholar 

  75. Lu YH, Lu JJ, Li XH, Zhu H, Fan XJ, Zhu SJ, et al. MiR-200a inhibits epithelial-mesenchymal transition of pancreatic cancer stem cell. BMC Cancer. 2014;14. https://doi.org/10.1186/1471-2407-14-85

  76. Lahdaoui F, Delpu Y, Vincent A, Renaud F, Messager M, Duchene B, et al. miR-219-1-3p is a negative regulator of the mucin MUC4 expression and is a tumor suppressor in pancreatic cancer. Oncogene. 2015;34(6):780–8.

    Article  CAS  PubMed  Google Scholar 

  77. Wang CY, Liu PA, Wu HS, Cui PF, Li YF, Liu Y, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Oncotarget. 2016;7(12):14912–24.

    PubMed  PubMed Central  Google Scholar 

  78. Li X, Deng SJ, Zhu S, Jin Y, Cui SP, Chen JY, et al. Hypoxia-induced lncRNA-NUTF2P3-001 contributes to tumorigenesis of pancreatic cancer by derepressing the miR-3923/KRAS pathway. Oncotarget. 2016;7(5):6000–14.

    PubMed  PubMed Central  Google Scholar 

  79. Liu N, Sun YY, Zhang XW, Chen S, Wang Y, Zhang ZX, et al. Oncogenic miR-23a in pancreatic ductal adenocarcinogenesis via inhibiting APAF1. Dig Dis Sci. 2015;60(7):2000–8.

    Article  CAS  PubMed  Google Scholar 

  80. Li P, Xu Q, Zhang D, Li X, Han L, Lei J, et al. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. FEBS Lett. 2014;588(5):705–12.

    Article  CAS  PubMed  Google Scholar 

  81. Chen MY, Wang M, Xu SM, Guo XJ, Jiang JX. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Oncotarget. 2015;6(42):44466–79.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu J, et al. MicroRNA-191 promotes pancreatic cancer progression by targeting USP10. Tumour Biol. 2014;35(12):12157–63.

    Article  CAS  PubMed  Google Scholar 

  83. Ren ZG, Dong SX, Han P, Qi J. miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. Oncol Rep. 2016;35(3):1365–74.

    Article  CAS  PubMed  Google Scholar 

  84. Keklikoglou I, Hosaka K, Bender C, Bott A, Koerner C, Mitra D, et al. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene. 2015;34(37):4867–78.

    Article  CAS  PubMed  Google Scholar 

  85. Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H, et al. miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1. J Exp Clin Cancer Res. 2014;33(54). https://doi.org/10.1186/1756-9966-33-54

    Article  CAS  Google Scholar 

  86. Xu QH, Li P, Chen X, Zong L, Jiang ZD, Nan LG, et al. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Oncotarget. 2015;6(16):14153–64.

    PubMed  PubMed Central  Google Scholar 

  87. Xia X, Zhang K, Cen G, Jiang T, Cao J, Huang K, et al. MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Oncotarget. 2015;6(25):21046–63.

    Article  PubMed  PubMed Central  Google Scholar 

  88. He D, Miao HL, Xu YM, Xiong LH, Wang Y, Xiang HX, et al. MiR-371-5p facilitates pancreatic cancer cell proliferation and decreases patient survival. PLoS One. 2014;9(11):e112930.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  89. Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014;6(1):22–33.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, et al. The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer. Int J Cancer. 2016; https://doi.org/10.1002/ijc.30291.

  91. Vila-Navarro E, Vila-Casadesus M, Moreira L, Duran-Sanchon S, Sinha R, Gines A, et al. MicroRNAs for detection of pancreatic neoplasia: biomarker discovery by next-generation sequencing and validation in 2 independent cohorts. Ann Surg. 2016;265:1226–1234.

    Article  PubMed  Google Scholar 

  92. Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang YH, Georgeades C, et al. Plasma microRNAs as novel biomarkers for patients with intraductal papillary mucinous neoplasms of the pancreas. Cancer Prev Res. 2015;8(9):826–34.

    Article  CAS  Google Scholar 

  93. Humeau M, Torrisani J, Cordelier P. miRNA in clinical practice: pancreatic cancer. Clin Biochem. 2013;46(10–11):933–6.

    Article  CAS  PubMed  Google Scholar 

  94. Weber JA, Baxter DH, Zhang SL, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. 2010;56(11):1733–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Kahlert C, Melo SA, Protopopov A, Tang JB, Seth S, Koch M, et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem. 2014;289(7):3869–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  96. Villarroya-Beltri C, Baixauli F, Gutierrez-Vazquez C, Sanchez-Madrid F, Mittelbrunn M. Sorting it out: regulation of exosome loading. Semin Cancer Biol. 2014;28:3–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A, et al. Intercellular transfer of the oncogenic receptor EGFrvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008;10(5):619–U24.

    Article  CAS  PubMed  Google Scholar 

  98. Raposo G, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol. 2013;200(4):373–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Kosaka N, Yoshioka Y, Fujita Y, Ochiya T. Versatile roles of extracellular vesicles in cancer. J Clin Investig. 2016;126(4):1163–72.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Robinson SM, Fan L, White SA, Charnley RM, Mann J. The role of exosomes in the pathogenesis of pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. 2016;75:131–9.

    Article  CAS  PubMed  Google Scholar 

  101. Keller S, Ridinger J, Rupp AK, Janssen JWG, Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9. https://doi.org/10.1186/1479-5876-9-86

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Lau C, Kim Y, Chia D, Spielmann N, Eibl G, Elashoff D, et al. Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem. 2013;288(37):26888–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Jin Y, Chen K, Wang Z, Wang Y, Liu J, Lin L, et al. DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer. 2016;16(1):753.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10(12):1470–U209.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3. https://doi.org/10.3402/jev.v3.23743

    Article  CAS  Google Scholar 

  106. Kanwar SS, Dunlay CJ, Simeone DM, Nagrath S. Microfluidic device (ExoChip) for on-chip isolation, quantification and characterization of circulating exosomes. Lab Chip. 2014;14(11):1891–900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523(7559):177–U82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Greening DW, Kapp EA, Ji H, Speed TP, Simpson RJ. Colon tumour secretopeptidome: insights into endogenous proteolytic cleavage events in the colon tumour microenvironment. Biochim Biophys Acta. 2013;1834(11):2396–407.

    Article  CAS  PubMed  Google Scholar 

  109. Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M. A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer. Cancer Lett. 2017;393:86–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Javeed N, Sagar G, Dutta SK, Smyrk TC, Lau JS, Bhattacharya S, et al. Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin Cancer Res. 2015;21(7):1722–33.

    Article  CAS  PubMed  Google Scholar 

  111. Que RS, Ding GP, Chen JH, Cao LP. Analysis of serum exosomal microRNAs and clinicopathologic features of patients with pancreatic adenocarcinoma. World J Surg Oncol. 2013;11. https://doi.org/10.1186/1477-7819-11-219.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Joshi GK, Deitz-McElyea S, Liyanage T, Lawrence K, Mali S, Sardar R, et al. Label-free nanoplasmonic-based short noncoding RNA sensing at attomolar concentrations allows for quantitative and highly specific assay of microRNA-10b in biological fluids and circulating exosomes. ACS Nano. 2015;9(11):11075–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Madhavan B, Yue SJ, Galli U, Rana S, Gross W, Muller M, et al. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer. 2015;136(11):2616–27.

    Article  CAS  PubMed  Google Scholar 

  114. Machida T, Tomofuji T, Maruyama T, Yoneda T, Ekuni D, Azuma T, et al. miR1246 and miR4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. Oncol Rep. 2016;36(4):2375–81.

    Article  CAS  PubMed  Google Scholar 

  115. Zhang P, He M, Zeng Y. Ultrasensitive microfluidic analysis of circulating exosomes using a nanostructured graphene oxide/polydopamine coating. Lab Chip. 2016;16(16):3033–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Cho S, Jo W, Heo Y, Kang JY, Kwak R, Park J. Isolation of extracellular vesicle from blood plasma using electrophoretic migration through porous membrane. Sens Actuat B Chem. 2016;233:289–97.

    Article  CAS  Google Scholar 

  117. Lotvall J, Hill AF, Hochberg F, Buzas EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.

    Article  PubMed  Google Scholar 

  118. Lee ES, Lee JM. Imaging diagnosis of pancreatic cancer: a state-of-the-art review. World J Gastroenterol. 2014;20(24):7864–77.

    Article  PubMed  PubMed Central  Google Scholar 

  119. Zhang J, Zuo CJ, Jia NY, Wang JH, Hu SP, Yu ZF, et al. Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer. World J Gastroenterol. 2015;21(10):2988–96.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Xu YP, Yang M. Advancement in treatment and diagnosis of pancreatic cancer with radiopharmaceuticals. World J Gastrointest Oncol. 2016;8(2):165–72.

    Article  PubMed  PubMed Central  Google Scholar 

  121. Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, et al. Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging. 2012;39(5):846–51.

    Article  CAS  PubMed  Google Scholar 

  122. Di Gangi IM, Mazza T, Fontana A, Copetti M, Fusilli C, Ippolito A, et al. Metabolomic profile in pancreatic cancer patients: a consensus-based approach to identify highly discriminating metabolites. Oncotarget. 2016;7(5):5815–29.

    Article  PubMed  PubMed Central  Google Scholar 

  123. Ritchie SA, Akita H, Takemasa I, Eguchi H, Pastural E, Nagano H, et al. Metabolic system alterations in pancreatic cancer patient serum: potential for early detection. BMC Cancer. 2013;13:416.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Ritchie SA, Chitou B, Zheng Q, Jayasinghe D, Jin W, Mochizuki A, et al. Pancreatic cancer serum biomarker PC-594: diagnostic performance and comparison to CA19-9. World J Gastroenterol. 2015;21(21):6604–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Mayerle J, Kalthoff H, Reszka R, Kamlage B, Peter E, Schniewind B, et al. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Gut. 2017; https://doi.org/10.1136/gutjnl-2016-312432.

  126. Fukutake N, Ueno M, Hiraoka N, Shimada K, Shiraishi K, Saruki N, et al. A novel multivariate index for pancreatic cancer detection based on the plasma free amino acid profile. PLoS One. 2015;10(7):e0132223.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. Nat Med. 2011;17(4):448–U83.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  129. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers for cancer. J Clin Oncol. 2010;28(4):698–704.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, L69 3GE, UK

    Lucy Oldfield, Rohith Rao, Lawrence N. Barrera & Eithne Costello

Authors
  1. Lucy Oldfield
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rohith Rao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence N. Barrera
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eithne Costello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eithne Costello .

Editor information

Editors and Affiliations

  1. Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany

    John P. Neoptolemos

  2. Division of Research Department of Surgery and Genomic Sciences and Precision Medicine Center (GSPMC), Medical College of Wisconsin, Milwaukee, Wisconsin, USA

    Raul Urrutia

  3. Division of Medical Oncology, Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA

    James L. Abbruzzese

  4. Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany

    Markus W. Büchler

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Science+Business Media, LLC, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Oldfield, L., Rao, R., Barrera, L.N., Costello, E. (2018). Development of Novel Diagnostic Pancreatic Tumor Biomarkers. In: Neoptolemos, J., Urrutia, R., Abbruzzese, J., Büchler, M. (eds) Pancreatic Cancer. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7193-0_86

Download citation

Publish with us

Policies and ethics

Search

Navigation